Comparative pharmacoeconomic effectiveness of menopausal hormone therapy: oral versus transdermal preparations
- 作者: Astapovskii A.A.1, Drozdov V.N.1, Astapovskaya O.V.1, Shikh E.V.1
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- 期: 编号 12 (2024)
- 页面: 186-192
- 栏目: Guidelines for the Practitioner
- URL: https://journals.rcsi.science/0300-9092/article/view/282542
- DOI: https://doi.org/10.18565/aig.2024.307
- ID: 282542
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Objective: To evaluate the economic benefit of transdermal menopausal hormone therapy (MHT) compared to the oral treatment using the method of scientific modeling.
Materials and methods: Clinical economic modeling was used to conduct the pharmacoeconomic analysis. The results of published studies were used as sources for the effectiveness analysis. The Scottish Intercollegiate Guidelines Network (SIGN) methodology, with a minimum level of evidence of 2, was used to select studies, perform clinical and economic modeling, develop the study design, and assess the methodological quality of the studies. A pharmacoeconomic analysis was conducted to compare two regimens of menopausal hormone therapy and assess the risk of adverse complications, namely venous thromboembolism (VTE) and acute circulatory failure (ACF).
Results: The pharmacoeconomic analysis showed that the use of MHT with transdermal estradiol (Oestrogel) in continuous mode demonstrated efficiency in cost savings due to the reduction of costs for the treatment of adverse events (VTE and ACF) and their consequences; savings per one patient amount to 6,389.4 rubles per year. Savings per 1,000 women during the year will amount to 6,389,400 rubles, or 31,947,000 rubles for 5 years.
Conclusion: Transdermal MHT may prove to be cost-effective compared to oral MHT due to the reduced cost of complications associated with oral MHT. The use of the Oestrogel preparation will reduce the total cost of MHT by 11.3% compared to oral MHT.
作者简介
Alexandr Astapovskii
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
编辑信件的主要联系方式.
Email: al.astapovskii@gmail.com
ORCID iD: 0000-0002-7430-3341
PhD, Associate Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
俄罗斯联邦, 119048, Moscow, Trubetskaya str., 8-2Vladimir Drozdov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: vndrozdov@yandex.ru
ORCID iD: 0000-0002-0535-2916
Dr. Med. Sci., Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
俄罗斯联邦, 119048, Moscow, Trubetskaya str., 8-2Olga Astapovskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: olgunnnnn@gmail.com
obstetrician-gynecologist, V.V. Veresaev City Clinical Hospital DZM
俄罗斯联邦, 119048, Moscow, Trubetskaya str., 8-2Evgenia Shikh
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: chih@mail.ru
ORCID iD: 0000-0001-6589-7654
Dr. Med. Sci., Head of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases
俄罗斯联邦, 119048, Moscow, Trubetskaya str., 8-2参考
- NICE: Menopause, diagnosis and management - from Guideline to Practice Guideline Summary. Available at: https://thebms.org.uk/wp-content/uploads/2022/12/09-BMS-TfC-NICE-Menopause-Diagnosis-and-Management-from-Guideline-to-Practice-Guideline-Summary-NOV2022-A.pdf
- Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. https://dx.doi.org/10.1097/gme.0b013e31824d8f40.
- Schoenaker D.A., Jackson C.A., Rowlands J.V., Mishra G.D. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int. J. Epidemiol. 2014; 43(5): 1542-62. https://dx.doi.org/10.1093/ije/dyu094.
- ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet. Gynecol. 2014; 123(1): 202-16. https://dx.doi.org/10.1097/01.AOG.0000441353.20693.78.
- Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (Протокол лечения). М.; 2015: 8-9. [Sukhikh G.T., Smetnik V.P., Andreeva E.N., Balan V.E., Gavisova A.A., Grigoryan O.R., Ermakova E.I., Zaidieva Ya.Z., Il’ina L.M., Kasyan V.N., Marchenko L.A., Podzolkova N.M., Rogovskaya S.I., Smetnik A.A., Chernukha G.E., Yureneva S.V. Menopausal hormone therapy and maintaining the health of women in adulthood. Clinical guidelines (Treatment protocol). Moscow; 2015: 8-9. (in Russian)].
- Юренева С.В. Менопаузальная гормональная терапия – индивидуализированный подход с позиции эффективности и безопасности: обзор международных рекомендаций. Акушерство и гинекология. 2024; 9: 36-46. [Yureneva S.V. Efficacy and safety of personalized menopausal hormone therapy: a review of international guidelines. Obstetrics and Gynecology. 2024; (9): 36-46. (in Russian)]. https://dx.doi.org/10.18565/aig.2024.224.
- Steinkellner A.R., Denison S.E., Eldridge S.L., Lenzi L.L., Chen W., Bowlin S.J. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women’s Health Initiative. Menopause. 2012; 19(6): 616-21. https://dx.doi.org/10.1097/gme.0b013e31824bb039.
- Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7): 605-13. https://dx.doi.org/10.1001/jama.280.7.605.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women. 2021. (in Russian)].
- Stuenkel C.A. Reproductive milestones across the lifespan and cardiovascular disease risk in women. Climacteric. 2023; 27(1): 5-15. https://dx.doi.org/10.1080/13697137.2023.2259793.
- Шляхто Е.В., Сухих Г.Т., Серов В.Н., Дедов И.И., Арутюнов Г.П., Сучков И.А. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ Российского кардиологического общества, Российского общества акушеров-гинекологов, Российской ассоциации эндокринологов, Евразийской ассоциации терапевтов, Ассоциации флебологов России. Акушерство и гинекология. 2023; 11: 211-32. [Shlyakhto E.V., Sukhikh G.T., Serov V.N., Dedov I.I., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for menopausal hormone therapy in patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Russian Phlebological Association. Obstetrics and Gynecology. 2023; (11): 211-32. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.267.
- Goldštajn M.Š., Mikuš M., Ferrari F.A., Bosco M., Uccella S., Noventa M. et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch. Gynecol. Obstet. 2023; 307(6): 1727-45. https://dx.doi.org/10.1007/s00404-022-06647-5.
- Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. https://dx.doi.org/10.1136/bmj.k4810.
- Renoux C., Dell'Aniello S., Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 2010; 8(5): 979-86. https://dx.doi.org/10.1111/j.1538-7836.2010.03839.x.
- Simon J.A., Laliberté F., Duh M.S., Pilon D., Kahler K.H., Nyirady J. et al. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. Menopause. 2016; 23(6): 600-10. https://dx.doi.org/10.1097/GME.0000000000000590.
- Sweetland S., Beral V., Balkwill A., Liu B., Benson V.S., Canonico M. et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 2012; 10(11): 2277-86. https://dx.doi.org/10.1111/j.1538-7836.2012.04919.x.
- Løkkegaard E., Andreasen A.H., Jacobsen R.K., Nielsen L.H., Agger C., Lidegaard Ø. Hormone therapy and risk of myocardial infarction: a national register study. Eur. Heart J. 2008; 29(21): 2660-8. https://dx.doi.org/10.1093/eurheartj/ehn408.
- Renoux C., Dell’aniello S., Garbe E., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010; 340: c2519. https://dx.doi.org/10.1136/bmj.c2519.
- Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта при приеме менопаузальной гормональной терапии. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2020; 6(4): 23-53. [Ulumbekova G.E., Khudova I.Yu. Demographic, social and economic effects of menopause hormonal therapy. Healthcare Management: News, Views, Education. Bulletin of VSHOUZ. 2020; 6(4): 23-53. (in Russian)]. https://dx.doi.org/10.24411/2411-8621-2020-14002.
补充文件
